Organogenesis Holdings Inc (ORGO) FinancialsORGOOrganogenesis Holdings Inc

Organogenesis Holdings Inc. (ORGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Advanced Wound Care, accounting for 92.0% of total sales, equivalent to $92.70M. Another important revenue stream is Surgical & Sports Medicine. Understanding this composition is critical for investors evaluating how ORGO navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Organogenesis Holdings Inc. maintains a gross margin of 45.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -107.60%, while the net margin is -220.01%. These profitability ratios, combined with a Return on Equity (ROE) of -53.31%, provide a clear picture of how effectively ORGO converts its operational activities into shareholder value.

In the context of the broader market, ORGO competes directly with industry leaders such as KEQU and AGPU. With a market capitalization of $108.07M, it holds a leading position in the sector. When comparing efficiency, ORGO's gross margin of 45.90% stands against KEQU's 29.61% and AGPU's 6.27%. Such benchmarking helps identify whether Organogenesis Holdings Inc. is trading at a premium or discount relative to its financial performance.

Organogenesis reported a significant decline in revenue, with Q1 2026 revenue at $36.3 million, down 58% year-over-year, and a net loss of $56.2 million, indicating serious profitability issues.